L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats.
Bronchopulmonary dysplasia (BPD) is characterized by arrested alveolar development and complicated by pulmonary hypertension (PH). NO promotes alveolar growth. Inhaled NO (iNO) ameliorates the BPD phenotype in experimental models and in some premature infants. Arginosuccinate synthetase (ASS) and arginosuccinate lyase (ASL) convert L-citrulline to L-arginine; L-citrulline is regenerated during NO synthesis from L-arginine. Plasma levels of these NO precursors are low in PH. We hypothesized that L-citrulline prevents experimental O2-induced BPD in newborn rats. Rat pups were assigned from birth through postnatal day (P) 14 to room air (RA), RA + L-citrulline, 95% hyperoxia (BPD model), and 95%O2 + L-citrulline. Rat pups exposed to hyperoxia had fewer and enlarged air spaces and decreased capillary density, mimicking human BPD. This was associated with decreased plasma L-arginine and L-citrulline concentrations on P7. L-citrulline treatment significantly increased plasma L-arginine and L-citrulline concentrations and increased ASL protein expression in hyperoxia. L-citrulline preserved alveolar and vascular growth in O2-exposed pups and decreased pulmonary arterial medial wall thickness (MWT) and right ventricular hypertrophy (RVH). Increased lung arginase (ARG) activity in O2-exposed pups was reversed by L-citrulline treatment. L-citrulline supplementation prevents hyperoxia-induced lung injury and PH in newborn rats. L-citrulline may represent a novel therapeutic alternative to iNO for prevention of BPD.
Vadivel
Arul
A
Department of Pediatrics, Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta T6G 2S2, Canada.
Aschner
Judy L
JL
Rey-Parra
Gloria J
GJ
Magarik
Jordan
J
Zeng
Heng
H
Summar
Marshall
M
Eaton
Farah
F
Thébaud
Bernard
B
D000818:Animals; D000831:Animals, Newborn; D001120:Arginine / Q000097:blood; D001997:Bronchopulmonary Dysplasia / Q000097:blood / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control*; D002956:Citrulline / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology / Q000517:prevention & control*; D007231:Infant, Newborn; D008168:Lung / Q000473:pathology / Q000503:physiopathology; D055370:Lung Injury; D009569:Nitric Oxide / Q000097:blood; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000254:growth & development* / Q000503:physiopathology; D051381:Rats
D002956:Citrulline; D009569:Nitric Oxide; D001120:Arginine
Circulation. 2005 Oct 18;112(16):2477-86
16230500
Am J Physiol Lung Cell Mol Physiol. 2005 Mar;288(3):L450-9
15591412
J Biol Chem. 2004 Apr 30;279(18):18353-60
14970240
Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L555-64
19136580
Annu Rev Physiol. 2005;67:623-61
15709973
Acta Physiol Scand. 2003 Oct;179(2):115-22
14510774
Curr Opin Clin Nutr Metab Care. 2008 Jan;11(1):55-61
18090660
N Engl J Med. 2006 Jul 27;355(4):343-53
16870913
Am J Physiol Lung Cell Mol Physiol. 2002 Mar;282(3):L379-85
11839530
Mol Genet Metab. 2008 Aug;94(4):397-402
18562231
Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L498-504
18192591
JAMA. 2005 Jul 6;294(1):81-90
15998894
Am J Physiol. 1998 Jul;275(1):L96-102
9688940
Nitric Oxide. 2001 Apr;5(2):187-97
11292368
Circ Res. 2004 Apr 30;94(8):1115-23
15016731
J Natl Med Assoc. 2001 Oct;93(10):363-71
11688916
N Engl J Med. 2003 Nov 27;349(22):2099-107
14645637
N Engl J Med. 2001 Jun 14;344(24):1832-8
11407344
Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L313-21
12679322
Am J Respir Crit Care Med. 2005 Oct 1;172(7):899-906
15976381
J Nutr. 2004 Oct;134(10 Suppl):2743S-2747S; discussion 2765S-2767S
15465778
Eur Respir J. 2008 Aug;32(2):321-8
18385172
J Immunol Methods. 1994 Sep 14;174(1-2):231-5
8083527
Pediatr Pulmonol. 2007 Jan;42(1):3-9
17123320
J Appl Physiol (1985). 2004 Feb;96(2):725-30
14565964
Lancet. 2006 Apr 29;367(9520):1421-31
16650652
Hypertension. 2004 Feb;43(2):186-91
14718356
Am J Physiol Lung Cell Mol Physiol. 2008 Jan;294(1):L34-45
17934065
Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):275-90
17214603
N Engl J Med. 2008 Feb 14;358(7):743-5; author reply 745-6
18272900
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1523-8
16166623
J Thorac Cardiovasc Surg. 2006 Jul;132(1):58-65
16798303
J Nutr. 2004 Oct;134(10 Suppl):2820S-2825S; discussion 2853S
15465793
J Thorac Cardiovasc Surg. 2007 Aug;134(2):319-26
17662768
J Pediatr. 2003 Jan;142(1):26-30
12520250
Am J Respir Crit Care Med. 2005 Sep 15;172(6):750-6
15947285
Circulation. 2006 Apr 4;113(13):1708-14
16585403
Am J Physiol Lung Cell Mol Physiol. 2006 Jul;291(1):L119-27
16443642
Am J Physiol Lung Cell Mol Physiol. 2003 Jun;284(6):L964-71
12588707
Am J Respir Crit Care Med. 2007 May 15;175(10):978-85
17272782
Am J Respir Crit Care Med. 2004 Jul 15;170(2):148-53
15070820
Pediatrics. 2008 Feb;121(2):317-25
18245423
Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):193-7
8419922
N Engl J Med. 1993 Dec 30;329(27):2002-12
7504210
J Cereb Blood Flow Metab. 1997 Aug;17(8):884-93
9290586
Arch Histol Cytol. 1997 Dec;60(5):477-92
9477156
N Engl J Med. 2006 Jul 27;355(4):354-64
16870914
Am J Physiol Lung Cell Mol Physiol. 2009 Sep;297(3):L506-11
19617312